CryoLife, Inc. Introduces Heart Valve Warranty
Steven G. Anderson, President and Chief Executive Officer of
CryoLife, said, "To our knowledge, this lifetime limited warranty on
heart valves is the first such warranty in the heart valve replacement
business, and we believe that it clearly demonstrates that our
cryopreserved heart valves should be recognized as the gold standard
in our industry. The lifetime warranty highlights our confidence in
our cryopreservation process for physicians and patients. Clinical
data recently presented at the American College of Cardiology and
historical published data indicate that over 90% of the CryoLife heart
valves implanted are free from structural deterioration at ten years.
These data clearly indicate the absence of valve related endocarditis
and thromboembolic events in CryoLife's cryopreserved heart valves."
Founded in 1984, CryoLife, Inc. is the leader in the development
and commercialization of implantable living human tissues for use in
cardiovascular, vascular, and orthopaedic surgeries throughout the
United States and Canada. The Company's BioGlue(R) Surgical Adhesive,
CE marked in the European Union for use in vascular and pulmonary
sealing and repair, is distributed throughout Europe. The Company also
manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless
porcine heart valves which are distributed within the European
Community.
Statements made in this press release which look forward in time
involve risks and uncertainties and are "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act of
1995. Such risks and uncertainties include the possibility of improper
implantation of allograft valves by surgeons, the potential impact of
a patient's preexisting endocarditis or other abnormalities, the
potential impact of an allograft recipient's intravenous drug use or
other introduction of bacteria into the recipient's bloodstream,
changes in economic cycles, competition from other companies, changes
in laws and governmental regulations applicable to the Company and
other risk factors detailed in the Company's Securities and Exchange
Commission filings, including the Company's Prospectus dated
March 30, 1998, contained in its Registration Statement on Form S-3
(No. 333-46545.)
Editor's Note:
CryoLife Customer Service may be accessed by telephone:
1-800-438-8285 (U.S. and Canada)
1-770-419-3355 (International)
1-770-590-3753 (International fax)
E-mail: customerservice@cryolife.com
For additional information about the Company, visit CryoLife's
web site: http://www.cryolife.com
--30--
CONTACT: CryoLife Inc., Atlanta
Roy Vogeltanz, 800/438-8285